China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website

June 29, 2010

BEIJING, June 29 /PRNewswire-Asia-FirstCall/ — China Medical Technologies,
Inc. (the “Company”) (Nasdaq: CMED), a leading China-based advanced in-vitro
diagnostic (“IVD”) company, today announced the recent publication of a large
sample study on the Company’s SPR analyzer and related HPV DNA chip (the “SPR
System”) for the detection of 16 high risk and 8 low risk genotypes of human
papillomavirus (“HPV”). The study tested specimens of 560 patients with
atypical squamous cells of undetermined significance (“ASCUS”) or above using
the SPR System and compared the results with sequence analysis. The study
concluded that the SPR System is highly sensitive and specific in HPV
genotyping (99% concordance between the SPR System and sequence analysis) and
can become an effective approach for HPV genotyping in a clinical setting.

The study is entitled, “A Surface Plasmon Resonance-based System to
Genotype Human Papillomavirus”, and can be found in the online edition of the
medical journal Cancer Genetics and Cytogenetics, Volume 200, Issue 2, at
http://cancergeneticsjournal.org .

The Company also announced the creation of a new column “Medical
Publications” in its investor relations section at http://ir.chinameditech.com
which currently posts 12 articles from Chinese medical publications. The
articles related to the use of the Company’s FISH products in various
applications including prenatal diagnosis, cancer detection and companion
diagnostic for targeted cancer drugs. The Company plans to update the column
periodically to add medical publications related to the Company’s products
following approval from the authors.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD
company using molecular diagnostic technologies including Fluorescent in situ
Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an
immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA),
to develop, manufacture and distribute diagnostic products used for the
detection of various cancers, diseases and disorders as well as companion
diagnostic tests for targeted cancer drugs. The Company generates all of its
revenues in China through the sale of diagnostic consumables including FISH
probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are
recurring users of the consumables for their patients. The Company sells FISH
probes and SPR chips to large hospitals through its direct sales force and
ECLIA reagent kits to small and mid-size hospitals through distributors. For
more information, please visit http://www.chinameditech.com .

    For more information, please contact:

     Winnie Yam
     Tel:   +852-2511-9808
     Email: IR@chinameditech.com

SOURCE China Medical Technologies, Inc.

Source: newswire

comments powered by Disqus